Fibroblast Growth Factor: A Comprehensive Exploration from Basic Biology to Clinical Applications

I. What is Fibroblast Growth Factor? What role does it play in the human body?

Fibroblast Growth Factors (FGFs) are a large and multifunctional family of signaling proteins. Since their discovery in the 1940s, they have become a central topic in cell biology, developmental science, and medical research. The FGFs family currently consists of 23 known members (FGF1 to FGF23 in humans), which regulate a series of critical life processes by binding to specific receptors (FGFRs) on the cell surface and activating complex intracellular signaling networks. The functions of FGFs extend far beyond what their name suggests, as they are not limited to acting solely on fibroblasts. Instead, they are among the most critical "multitaskers" in the human body. During embryonic development, FGF signaling pathways guide the formation of limb buds, neural tube development, and organogenesis, participating in almost all stages of construction from a fertilized egg to a complete organism. In adults, FGFs function to maintain homeostasis, regulating tissue repair and regeneration. When tissues are damaged—whether it be skin wounds, bone fractures, or vascular injuries—specific FGFs are rapidly activated to promote cell proliferation, migration, and differentiation, while also inducing angiogenesis to provide nutrients and oxygen for the repair process. Additionally, FGFs play a central role in metabolic balance, particularly FGF19, FGF21, and FGF23, which are known as "endocrine FGFs." These molecules circulate throughout the body like hormones, precisely regulating the metabolism of phosphate, vitamin D, bile acids, and glucose. Thus, from embryonic construction to wound healing and metabolic regulation in adulthood, the FGFs family is an indispensable language of intercellular communication that persists throughout life.

II. How does the signaling mechanism of FGFs work? How is the family classified?

The complexity of the FGFs family necessitates a precise and tightly regulated signaling mechanism. Its mode of action primarily relies on the formation of a ternary complex consisting of the FGF ligand, FGFR receptor, and heparan sulfate proteoglycans (HSPGs). FGFRs are transmembrane proteins with tyrosine kinase activity. When an FGF ligand binds to FGFR, HSPGs—present on the cell surface and in the extracellular matrix—act as "co-receptors" to stabilize the binding and promote receptor dimerization. After dimerization, the tyrosine kinase in the intracellular domain is activated, leading to autophosphorylation and the recruitment of downstream adapter proteins (such as FRS2 and PLCγ). This ultimately activates multiple signaling pathways, including RAS/MAPK, PI3K/AKT, STAT, and PLCγ/PKC. These pathways collectively regulate gene expression, proliferation, survival, migration, and differentiation in target cells.

Based on their phylogenetic evolution, sequence homology, mode of action, and function, the extensive FGFs family is divided into seven subfamilies (paracrine FGFs, canonical FGFs, endocrine FGFs, intracrine FGFs, etc.). The most representative subfamilies include:

·          Paracrine FGFs: Include most members such as FGF1, FGF2, FGF4, FGF7, FGF8, FGF9, and FGF10. They primarily act locally, have high affinity for HSPGs, and influence neighboring cells through short-distance diffusion, participating in tissue development and repair.

·          Endocrine FGFs: Include FGF19 (in humans), FGF21, and FGF23. These molecules are secreted into the bloodstream like hormones and act on distant target organs. To adapt to systemic circulation, they have low affinity for HSPGs but require specific Klotho protein family co-receptors (α-Klotho or β-Klotho) to activate FGFRs, thereby precisely regulating systemic processes such as bile acid synthesis, energy expenditure, and mineral metabolism.

·          Intracrine FGFs: Include FGF11 to FGF14. These are not secreted extracellularly but function within cells, primarily regulating voltage-gated ion channels and neuronal excitability, closely related to nervous system functions.

This precise classification and complex signaling mechanism ensure that the FGFs family can accurately regulate a wide range of distinct physiological processes in a spatiotemporally specific manner.

III. In which diseases do FGFs play a key role in onset and progression?

Given the central role of FGF signaling pathways in life processes, their dysregulation—whether due to overactivation or deficiency—can lead to a series of serious diseases. Cancer is the most well-known area of FGF/FGFR signaling abnormalities. In many types of tumors, such as bladder cancer, breast cancer, lung cancer, and multiple myeloma, amplification, mutation, or translocation of FGFR genes is frequently observed, resulting in constitutively activated receptors that continuously drive tumor cell proliferation, survival, invasion, and metastasis. Simultaneously, tumor cells utilize FGF-induced angiogenesis to supply blood to rapidly growing tumors. Therefore, the FGF/FGFR pathway has become a critical target for anticancer drug development.

In skeletal and metabolic diseases, FGF23 plays a vital role. Diseases such as X-linked hypophosphatemia (XLH) are caused by excessive FGF23 activity, leading to renal phosphate wasting and abnormal vitamin D metabolism, resulting in rickets and osteomalacia. Conversely, loss of FGF23 function causes hyperphosphatemia and tissue ectopic calcification. As a metabolic regulator, FGF21 has become an attractive target for treating obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH) due to its ability to improve insulin sensitivity, promote fatty acid oxidation, and increase energy expenditure.

Additionally, FGF abnormalities are associated with various developmental disorders. For example, dominant-negative mutations in FGFR1-3 are the primary cause of craniosynostosis (e.g., Apert syndrome, Crouzon syndrome), where these mutations lead to premature fusion of cranial sutures, affecting brain development. Other FGFR mutations are closely related to limb development abnormalities, such as achondroplasia. In the field of wound healing, FGF2 and FGF7, which strongly promote granulation tissue formation, epithelial regeneration, and angiogenesis, have been developed as topical drugs for treating hard-to-heal chronic wounds, such as diabetic foot ulcers and pressure sores, demonstrating their significant therapeutic potential.

IV. What progress has been made in drug development targeting the FGF pathway? What challenges are faced?

Given the important role of the FGF/FGFR pathway in diseases, drug development targeting this pathway has become a hotspot in the biomedical industry, primarily focusing on two major classes of drugs: small-molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies. Small-molecule inhibitors (e.g., Erdafitinib, Pemigatinib) are designed to bind to the ATP-binding pocket of FGFRs, competitively inhibiting their tyrosine kinase activity. Some are pan-FGFR inhibitors, simultaneously targeting multiple FGFR subtypes, while others are selective inhibitors aimed at specific FGFRs (e.g., FGFR1-3) to reduce off-target effects. Drugs like Erdafitinib have been approved by the FDA for treating advanced bladder cancer and cholangiocarcinoma patients with specific FGFR mutations, marking a milestone in targeted FGF pathway therapy. Monoclonal antibodies adopt a different strategy by specifically binding to FGF ligands or FGFR receptors themselves to block ligand-receptor interactions. For example, Bemarituzumab is an antibody targeting FGFR2b that inhibits tumor growth by blocking ligand binding and mediating antibody-dependent cellular cytotoxicity (ADCC), showing promise in clinical trials for gastric cancer.

However, drug development targeting the FGF pathway is fraught with challenges. The primary issue is toxicity. Due to the fundamental role of the FGF pathway in normal physiological processes (e.g., phosphate metabolism, wound healing), inhibiting this pathway often leads to a series of side effects, most commonly hyperphosphatemia, nail toxicity, dry mouth, dry eyes, and fatigue. These mechanism-based toxicities often limit the dosage and duration of treatment. Secondly, the emergence of drug resistance is a challenge faced by almost all targeted therapies. Tumor cells may evade drug inhibition by activating alternative signaling pathways (e.g., MET or EGFR), generating new FGFR mutations, or altering feedback mechanisms. Additionally, drug selectivity is a major challenge. Developing highly selective inhibitors that can precisely distinguish between the four FGFR subtypes or even specific mutants is key to improving efficacy and reducing toxicity, but this is structurally challenging. Future research directions will focus on developing next-generation inhibitors with higher selectivity, exploring precision combination therapies tailored to specific genetic backgrounds (e.g., combined with immune checkpoint inhibitors), and devising new strategies to overcome resistance.

V. What are the future directions and application prospects of FGF research?

Research on the FGFs family is continuously deepening and expanding, with future directions full of exciting possibilities. In the field of regenerative medicine, the applications of FGFs extend far beyond current wound healing. Researchers are exploring the combination of FGF2, FGF9, and other members with biomaterial scaffolds to create biomimetic microenvironments for guiding nerve regeneration, repairing cartilage defects, and even regenerating entire organs. For example, in spinal cord injury models, FGFs have been shown to promote neuronal survival and axon regeneration; in post-myocardial infarction heart repair, FGFs can stimulate angiogenesis and improve cardiac function.

In the treatment of metabolic diseases, the development of drugs based on FGF21 and FGF1 analogs is intensifying. Long-acting engineered FGF21 analogs (e.g., Efruxifermin, Pegbelfermin) have shown potential in clinical trials for treating NASH, significantly improving liver steatosis, inflammation, and fibrosis. FGF1 has also been found to have potent glucose-lowering effects, and its localized administration (e.g., intraocular injection) may avoid systemic side effects, offering new approaches for diabetes treatment.

Novel drug modalities will also bring innovation to targeting the FGF pathway. In addition to small molecules and antibodies, new technologies such as bispecific antibodies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis-targeting chimeras) are being applied in this field to achieve more precise targeting, greater efficacy, and reduced resistance. Finally, ongoing exploration of the basic biology of FGFs remains the foundation for all applications. Scientists are still discovering new regulatory mechanisms of FGF signaling, new interacting proteins, and its unknown functions in the immune system, aging, and the nervous system. These fundamental discoveries will continue to open new pathways for treating major human diseases, ensuring that the Fibroblast Growth Factor family remains one of the most dynamic frontiers in life sciences and medical innovation.

Click on the product catalog numbers below to access detailed information on our official website.

Product Information